GIP receptor agonist; gastric inhibitory polypeptide receptor agonist; glucose-dependent insulinotropic polypeptide receptor agonist; GIPR agonist
Jump to navigation
Jump to search
Indications
- treatment of diabetes mellitus type-2 in the dual function hypoglycemic agent tirzepatide
- treatment of intracranial hypertension in combination with GLP-1 receptor agonist[3]
More general terms
More specific terms
Additional terms
- gastric inhibitory polypeptide receptor; GIP receptor; GIP-R; glucose-dependent insulinotropic polypeptide receptor (GIPR)
- gastric inhibitory polypeptide; glucose-dependent insulinotropic polypeptide (GIP)
References
- ↑ Fisman EZ, Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovasc Diabetol. 2021 Nov 24;20(1):225. PMID: https://pubmed.ncbi.nlm.nih.gov/34819089 PMCID: PMC8613929 Free PMC article.
- ↑ Gasbjerg LS, Rosenkilde MM, Meier JJ, Holst JJ, Knop FK. The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide. Diabetes Obes Metab. 2023 Nov;25(11):3079-3092. PMID: https://pubmed.ncbi.nlm.nih.gov/37551549 Review.
- ↑ 3.0 3.1 Stefanou M-I et al. Efficacy and safety of GLP-1 and dual GIP/GLP-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis. Eur J Neurol 2025 Sep; 32:e70358. PMID: https://pubmed.ncbi.nlm.nih.gov/40937960 PMCID: PMC12426903 https://pmc.ncbi.nlm.nih.gov/articles/PMC12426903/